Efficacy of Communication Modalities for Promoting Flu Shots
Assessing the Relative Efficacy of Communication Modalities for Messages Promoting Flu Shots
1 other identifier
interventional
43,225
1 country
1
Brief Summary
The purpose of this study is to test which modalities (mailed letter, short message service \[SMS\] text, or patient portal messages) are most effective for encouraging flu shots in high-risk patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Sep 2022
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 18, 2022
CompletedFirst Posted
Study publicly available on registry
August 22, 2022
CompletedStudy Start
First participant enrolled
September 6, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 4, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
October 4, 2022
CompletedOctober 12, 2022
October 1, 2022
28 days
August 18, 2022
October 6, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Flu vaccination
Flu vaccination within 4 weeks of the first message send date
4 weeks after the first messages are sent in the study
Other Outcomes (6)
High confidence flu diagnosis
Up to 8 months
"Likely flu" diagnosis
Up to 8 months
Flu complications
Up to 11 months
- +3 more other outcomes
Study Arms (6)
Control
NO INTERVENTIONNo additional pro-vaccination intervention - some patients are currently targeted for flu vaccination messages due to a non-machine learning-based assessment that they are at high risk for complications, but are not told that they are at high risk or that they have been targeted
Letter only
EXPERIMENTALThis group will receive a letter telling them they are at high risk for flu and complications
Patient portal only
EXPERIMENTALThis group will receive a patient portal message telling them they are at high risk for flu and complications
SMS only
EXPERIMENTALThis group will receive an SMS telling them they are at high risk for flu and complications
Patient portal + SMS
EXPERIMENTALThis group will receive a patient portal message and an SMS telling them they are at high risk for flu and complications
Letter + Patient portal + SMS
EXPERIMENTALThis group will receive a letter, a patient portal message, and an SMS telling them they are at high risk for flu and complications
Interventions
Patient portal message about flu vaccination
Eligibility Criteria
You may qualify if:
- Included on a list of active Geisinger patients (all patients on this list attended at least one primary care appointment at Geisinger between 10/1/2008 and 4/13/2022, and either had a Geisinger primary care provider assigned as of April 2022, or were in the Electronic Health Record \[EHR\] since at least September 2021 and had at least one encounter in 2020-2022)
- Aged 18 or older
- In the top 10% of risk for flu and flu complications, according to Medial's flu complications machine learning algorithm (which operates on coded EHR data)
- Has a Geisinger PCP assigned as of August 2022
- Has had an encounter in the last 2 years as of August 2022
You may not qualify if:
- \- Cannot be contacted via any of the communication modalities (e.g., letter, patient portal, SMS) being used in the study, either due to insufficient/missing contact information in the EHR or because they opted out of all modalities
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Geisinger Cliniclead
Study Sites (1)
Geisinger
Danville, Pennsylvania, 17822, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Christopher Chabris, PhD
Geisinger Clinic
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- CARE PROVIDER
- Masking Details
- Providers who prescribe vaccination and diagnose conditions will not be randomized to study arms or informed of patient assignment. Although patients will not be explicitly informed which arm they have been randomized to, they will be aware of the messages they receive.
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
August 18, 2022
First Posted
August 22, 2022
Study Start
September 6, 2022
Primary Completion
October 4, 2022
Study Completion
October 4, 2022
Last Updated
October 12, 2022
Record last verified: 2022-10
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP
- Time Frame
- The data will become available after publication of study results in a scientific journal and will be available as long as the Open Science Framework hosts the data.
- Access Criteria
- The data on the Open Science Framework will be open to anyone requesting that information.
Data with no personally identifiable information will be made available to other researchers on the Open Science Framework for transparency. This will include the essential data and code needed to replicate the analysis that yielded reported findings.